Source - SMW
Futura Medical said that all patients had now completed dosing in a European study of a treatment for erectile dysfunction.

Futura Medical said it remained on track to deliver headline data from the Phase 3 study by the end of 2019.

In addition, patient recruitment had recently been completed for the required 12 month open-label extension study.

'We are extremely pleased to have achieved this important milestone and look forward to the Phase 3 data read out, which is on track to deliver headline efficacy and safety data in December this year, a key value inflection point for the company,' chief executive James Barder said.

'It is estimated that one in six men will experience some form of erectile dysfunction in their lives.'

'We believe MED2005 will offer new hope to erectile dysfunction suffers, in an area that has seen little innovation for nearly two decades and has the potential to be a first line treatment option for erectile dysfunction.'


At 1:59pm: (LON:FUM) Futura Medical PLC share price was +2p at 33p



Related Charts

Futura Medical (FUM)

-0.50p (-1.65%)
delayed 12:56PM